Travere Therapeutics Stock
Travere Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Eric Dube
- Employees
- 497
- Market cap
- $4.7 B
- IPO
- 08/11/2012
Travere Therapeutics, Inc. is a biopharmaceutical company within the healthcare sector that focuses on developing therapies for rare kidney and metabolic diseases. Headquartered in San Diego, USA, and incorporated in Delaware, the company employs 497 people. Travere Therapeutics went public on November 8, 2012, and is…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Travere Therapeutics stock: price history
1D
-6.0%
1W
-4.9%
1M
-21.9%
6M
+21.7%
YTD
+29.8%
1Y
+80.3%
2Y
+174.8%
5Y
+102.4%
10Y
+140.2%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~10% stronger price swings than usual
Travere Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Travere Therapeutics develops and markets pharmaceutical therapies for rare kidney diseases and metabolic disorders. The core business focuses on the sale of medications such as FILSPARI, which is used to treat IgA nephropathy and FSGS, as well as Thiola for the treatment of cystinuria. The company generates revenues primarily through product sales, supplemented by licensing fees. Through its specialized focus on rare diseases, the company benefits from regulatory barriers to market entry through exclusive approvals for new medications.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Travere Therapeutics
Analyst assessment of Travere Therapeutics
PRICE TARGET LOW
US$67.00
CONSENSUS
US$76.00
MEDIAN
US$74.00
PRICE TARGET HIGH
US$89.00
0
STRONG BUY
15
BUY
3
HOLD
0
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 24/09/2026
Travere Therapeutics stock metrics
P/E
-110.22
P/B
189.08
EV/EBITDA
895.56
RETURN ON EQUITY
-141.9%
NET MARGIN
-20.5%
DEBT/EQUITY
25.16
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.0%
FLOAT SHARES
91,437,509
AVG. DAILY VOLUME (30D)
1,801,134
Insider transactions (SEC)
Cline Christopher R.
REED ELIZABETH E
REED ELIZABETH E
REED ELIZABETH E
ROTE WILLIAM E.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.0%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Travere Therapeutics stock
What does Travere Therapeutics do?
Travere Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Eric Dube, the company employs around 497 people.
The IPO was on 08/11/2012; the stock trades on NASDAQ under the ticker TVTX.
What do analysts say about Travere Therapeutics stock?
18 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$76.00, ranging from US$67.00 to US$89.00, with a median of US$74.00.
This is an external assessment, not a statement by Market Jury.
When does Travere Therapeutics report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 10% stronger than usual.
Does Travere Therapeutics pay a dividend?
No, Travere Therapeutics currently does not pay a dividend.
Which stocks are comparable to Travere Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Travere Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Travere Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.